MedTrace Logo

Evaluation of ATx201 as a Topical Antibiotic Agent

NCT03009734 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2018-03-20

No results posted yet for this study

Summary

AntibioTx is developping ATx201 as a topical product for treatment of skin infections, including infected atopic dermatitis.

Conditions

  • Infection, Bacterial

Interventions

DRUG

ATx201 dermal formulations 2%

Topical application of ATx201 dermal formulations 2%

Sponsors & Collaborators

  • UNION therapeutics

    lead INDUSTRY

Principal Investigators

  • Markus Zeitlinger, MD · General Hospital Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03009734 on ClinicalTrials.gov